At April 29, the share price of BioXcel was 46% higher than it was a year before, much better than the market return of around 8.5% (not including dividends) in the same period.
Yet BioXcel Therapeutics hasn’t reported any revenue yet, so it’s as much a business idea as an actual business, says Yahoo Finance.